NON-SQUAMOUS/SQUAMOUS NSCLC Clinical Trials

5 clinical trials for NON-SQUAMOUS/SQUAMOUS NSCLC across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• BEAMION PANTUMOR-1: A PHASE II, MULTICENTRE, MULTICOHORT, OPEN LABEL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZONGERTINIB (BI 1810631) FOR THE TREATMENT OF SELECTED HER2-MUTATED OR OVEREXPRESSED/AMPLIFIED SOLID TUMOURS — RECRUITING · PHASE2
• A PHASE III, RANDOMISED, OPEN-LABEL, GLOBAL STUDY OF DATOPOTAMAB DERUXTECAN (DATO-DXD) IN COMBINATION WITH RILVEGOSTOMIG (AZD2936) OR RILVEGOSTOMIG MONOTHERAPY VERSUS PEMBROLIZUMAB MONOTHERAPY FOR THE FIRST-LINE TREATMENT OF PARTICIPANTS WITH LOCALLY-ADVANCED OR METASTATIC NON-SQUAMOUS NSCLC WITH HIGH PD-L1 EXPRESSION (TC ¿ 50%) AND WITHOUT ACTIONABLE GENOMIC ALTERATIONS (TROPION-LUNG10) — RECRUITING · PHASE3
• A RANDOMIZED PHASE 3 STUDY OF DATOPOTAMAB DERUXTECAN (DATO-DXD) AND PEMBROLIZUMAB, WITH OR WITHOUT PLATINUM CHEMOTHERAPY, IN SUBJECTS WITH NO PRIOR THERAPY FOR ADVANCED OR METASTATIC PD-L1 TPS <50% NON-SQUAMOUS NON-SMALL CELL LUNG CANCER WITHOUT ACTIONABLE GENOMIC ALTERATIONS (TROPION-LUNG07) — RECRUITING · PHASE3
• A RANDOMIZED PHASE 3 STUDY OF SITRAVATINIB IN COMBINATION WITH NIVOLUMAB VERSUS DOCETAXEL IN PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER WITH DISEASE PROGRESSION ON OR AFTER PLATINUM-BASED CHEMOTHERAPY AND CHECKPOINT INHIBITOR THERAPY (SAPPHIRE) — COMPLETED · PHASE3
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III STUDY EVALUATING THE EFFICACY AND SAFETY OF PEMBROLIZUMAB PLUS PLATINUM-BASED DOUBLET CHEMOTHERAPY WITH OR WITHOUT CANAKINUMAB AS FIRST LINE THERAPY FOR LOCALLY ADVANCED OR METASTATIC NON-SQUAMOUS AND SQUAMOUS NON-SMALL CELL LUNG CANCER SUBJECTS (CANOPY-1) — COMPLETED · PHASE3

Refine this search